請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/40718
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 江文章(Wenchang Chiang) | |
dc.contributor.author | Fiona Wen-Szu Chang | en |
dc.contributor.author | 張文思 | zh_TW |
dc.date.accessioned | 2021-06-14T16:57:17Z | - |
dc.date.available | 2011-08-04 | |
dc.date.copyright | 2008-08-04 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-07-30 | |
dc.identifier.citation | 杜力軍,孫虹,李敏。荷葉大豆及其合劑調脂活性部位的研究。中草藥。2000, 31, 526-528。
肖華山,黃代青,傅文慶。荷葉對體外氧自由基的清除作用及其對果蠅壽命的影響。中國老年學雜誌。1996, 12, 373-375。 徐劍,黃元元,沈玲。複方荷葉沖劑降脂作用研究。中成藥。1989, 11, 24-25。 陳海光,曾慶孝。荷葉功能成分的提取及其對自由基清除作用的研究。食品與發酵工業。 2001, 27, 34-38。 陳海光,餘以剛。荷葉保健茶的研製及其功效研究。食品工業科技。 2002, 23, 53-54。 陶波,帥景賢,吳鳳蓮。荷葉水煎劑對高脂血症大鼠血脂及血液流變學的影響。中醫藥學報。2000, 28, 55-56。 龔康敏,魏克民。荷葉欽對高脂血症大鼠血脂及血流變學的影響。河南中醫。1999, 19, 28-29。 Bedir, E.; Tatli, I. I.; Khan, R. A.; Zhao, J.; Takamatsu, S.; Walker, L. A.; Goldman, P.; Khan, I. A. Biologically active secondary metabolites from Ginkgo biloba. J Agric Food Chem. 2002, 50, 3150-3155. Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001, 414, 813-820. Castelluccio, C.; Paganga, G.; Melikian, N.; Boldwell, G. P.; Pridham, J.; Sampson, J.; Rice, E. C. Antioxidant potential of intermediates in phenylpropanoid metabolism in higher plants. 1995, 368, 188-192. Chakravarthy, U.; Hayes, R. G.; Stitt, A. W.; McAuley, E.; Archer, D. B. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advance glycation end products. Diabetes. 1998, 47, 945-952. Chen, A. S.; Taguchi, T.; Sugiura, M.; Wakasugi, Y.; Kamei, A.; Wang, M. W.; Miwa, I. Pyridoxal-aminoguanidine adduct is more effective than aminoguanidine in preventing neuropathy and cataract in diabetic rats. Horm. Metab. Res. 2004, 36, 183-187. Chen, Y. C. Effects of vegetable and fruit components on the differentiation of 3T3-L1 preadipocytes. Master thesis of the National Taiwan University Graduate Institute of Horticulture: Taipei, Taiwan, 2003. Chen, Z.; Hu, Y.; Wu, H.; Jiang, H. Synthesis and biological evaluation of flavonoids as vasorelaxant agents. Bioorg. Med. Chem. Lett. 2004, 14,3949-3952. Chen, Y. T.; Hsieh, C. Y.; Li, C. K.; Liu, S. Y.; Wang, T. S. Inhibitory effects of the water yam (Dioscorea alata L.) on glucose-induced protein glycation: a comparative study with four Chinese medicine for treating diabetes. Nutri. Sci. D. 2006, 31, 137-145. Chibber, R.; Molinatti, P. A.; Wong, J. S.; Mirlees, D.; Kohner, E. M. The effect of aminoguanidine and toirestat on glucose toxicity in bovine retinal capillary pericytes. Diabetes. 1994, 43, 758-763. Coughlan, M.T.; Forbes, J.M.; Cooper, M.E. Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes. Kidney Int Suppl. 2007, 106, S54-60. Department of Health, Executive Yuan. Statistics of Causes of Death in 2006. Taipei, Taiwan, 2006, Du, J.; Suzuki, H.; Nagase, F.; Akhand, A. A.; Ma, X. Y.; Yokoyama, T.; Miyata, T.; Nakashima, I. Superoxide-mediated early oxidation and activation of ASK1 are important for initiating methylglyoxal-induced apoptosis process. Free Radic. Biol. Med. 2001, 31, 469-478. Fantuzzi, G. Adipose tissue, adipokines, and inflammation. J. Allergy Clin. Immunol. 2005, 115, 911-919. Flyvbjerg, A.; Denner, L.; Schrijvers, B. F.; Tilton, R. G.; Mogensen, T. H.; Paludan, S. R.; Rasch, R. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes. 2004, 53, 166-172. Forbes, J. M.; Soulis, T.; Thallas, V.; Panagiotopoulos, S.; Long, D. M.; Vasan, S.; Wagle, D.; Jerums, G.; Cooper, M. E. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia. 2001, 44, 108-114. Forbes, J. M.; Thallas, V.; Thomas, M. C.; Founds, H. W.; Burns, W. C.; Jerums, G.; Cooper, M. E. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J. 2003, 17, 1762-1764. Forbes, J. M.; Yee, L. T.; Thallas, V.; Lassila, M.; Candido, R.; Jandeleit-Dahm, K. A.; Thomas, M. C.; Burns, W. C.; Deemer, E. K.; Thorpe, S. R.; Cooper, M. E.; Allen, T. J. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes. 2004, 53, 1813-1823. Forbes, J.; Soldatos, G.; Thomas, M. C. Below the Radar: Advanced Glycation End Products that Detour “around the side”-Is HbA1c not an accurate enough predictor of long term progression and glycaemic control in diabetes. Clin. Biochem. Rev. 2005, 26, 123-134. Franz, M. J. Medical nutrition therapy for diabetes mellitus and hypoglycemia of nondiabetic origin. In Krause’s food, nutrition, and diet therapy. 11th edition. Mahan, K.; Escott-Stump, S., Eds.; Sauders: Philadelphia, PA, 2004, 792-837. Fukunaga, M.; Miyata, S.; Liu, B. F.; Miyazaki, H.; Hirota, Y.; Higo, S.; Hamada, Y.; Ueyama, S.; Kasuga, M. Methylglyoxal induces apoptosis through activation of p38 MAPK in rat Schwann cells. Biochem. Biophys. Res. Commun. 2004, 320, 689-695. Goh, S. Y.; Cooper, M. E. The role of advanced glycation end products in progress and complications of diabetes. J. Clin. Endocrinol. Metab. 2008, 94, 1143-1152. Han, J. S.; Rhee, A. H.; Cheigh, H. S. Changes of lipid in raw and processed adlay powder during storage. Korean J. Food Soc. Technol. 1988, 20, 691-698. Hayase, F.; Liang, Z. Q.; Suzuki, Y.; van Chuyen, N.; Shiuoda, T.; Kato, H. Enzymatic metabolism of 3-dexoyglucosone, a Maillard intermediate. Amino Acids. 1991, 1, 307-318. Ho, C. C. Effect of dehulled adlay on lipid and carbohydrate metabolism in STZ-induced diabetic rats. Master’s thesis of the department of food science of National Taiwan Ocean University: Keelung, Taiwan, 2000. Hofmann, S. M.; Dong, H. J.; Li, Zhu, Cai, W.; Altomonte, J.; Thung, S. N.; Zeng, F.; Fisher, E. A.; Vlassar, H. Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes. 2002, 51, 2081-2089. Horiuchi, S.; Unno, Y.; Usui, H.; Shikata, K.; Takaki, K.; Koito, W.; Sakamoto, Y.; Nagai, R.; Makino, K.; Sasao, A.; Wada, J.; Makino, H. Pathological roles of advanced glycation end product receptors SR-A and CD36. Ann. N.Y. Acad. Sci. 2005, 1043, 671-675. Hou, L.; Zhou, B.; Yang, L.; Liu, Z. L. Inhibition of human low density lipoprotein oxidation by flavonols and their glycosides. Chem Phys Lipids. 2004, 129, 209-219. Huang, H. The investigation on the interaction among anti-tumor compounds derived form adlay bran against human lung and colorectal cancer cells using combination index methodology. Master thesis of the National Taiwan University Graduate Institute of Food Science and Technology: Taipei, Taiwan, 2007. Hsia, S. M.; Yeh, C. L.; Kuo, Y. H.; Wang, P. S.; Chiang, W. Effects of adlay (Coix lachrymal-jobi L. var. ma-yuen Stapf.) hull extracts on the secretion of progesterone and estradiol in vivo and in vitro. Exp. Biol. Med. (Maywood). 2007, 232, 1181-1194. Hsu, H. Y. Oriental Material Medica- a concise guide. 1st Ed. Long Beach, CA: Oriental Healing Arts Institute. 1986, pp.280-281. Huebschmann, A. G.; Regensteiner, J. G. Diabetes and advanced glycation glycoxidation end products. Diabetes Care. 2006, 29, 1420-4131. Jia, X.; Olson, D. J.; Ross, A. R.; Wu, L. Structural and functional changes in human insulin induced by methylglyoxal. FASEB J. 2006, 20, 1555-1558. Jia, X.; Wu, L. Accumulation of endogenous methylglyoxal impaired insulin signaling in adipose tissue of fructose-fed rats. Mol. Cell Biochem. 2007, 306, 133-139. Jung, H. A.; Kim, J. E.; Chung, H. Y.; Choi, J. S. Antioxidant principles of Nelumbo nucifera stamens. Arch. Pharm. Res. 2003, 26, 279–285. Kang, T. H.; Jeong, S. J.; Kim, N. Y.; Higuchi, R.; Kim, Y. C. Sedative activity of two flavonol glycosides isolated from the flowers of Albizzia julibrissin Durazz. 2000, 71, 321-323. Kasai, H.; Fukada, S.; Yamaizumi, Z.; Sugie, S.; Mori, H. Action of chlorogenic acid in vegetables and fruits as an inhibitor of 8-hydroxydeoxyguanosine formation in vitro and in a rat carcinogenesis model. Food Chem. Toxicol. 2000, 38, 467-471. Kono, Y.; Shibata, H.; Kodama, Y.; Sawa, Y. The suppression of the N-nitrosating reaction by chlorogenic acid. Biochem. 1995, 312, 947-953. Koschinsky, T.; He, C. J.; Mitsuhashi, T.; Bucala, R.; Liu, C.; Buenting, C.; Heitmann, K.; Vlassara, H. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc. Natl. Acad. Sci. USA. 1997, 94, 6474-6479. Kunt, T.; Forst, T.; Whilhelm, A.; Tritschler, H.; Pfuetzner, A.; Harzer, L.; Engelbach, M. Zschaebitz, A.; Stofft, E.; Beyer, J. α-lipoic acid reduces expression of vascular cell adhesion molecule-1 and endothelial adhesion of human monocytes after stimulation with advanced glycation end products. Clin. Sci. (Lond.) 1999, 96, 75-82. Kuniyasu, A.; Ohgami, N.; Hayashi, S.; Miyazaki, A.; Horiuchi, S.; Nakayama, H. CD 36-mediated endocytic uptake of advanced glycation end products (AGE) in mouse 3T3-L1 and human subcutaneous adipocytes. FEBS. 2003, 537, 85-90. Kuo, C. C.; Chiang, W.; Liu, G. P.; Chien, Y. L.; Chang, J. Y.; Lee, C. K.; Lo, J. M.; Huang, S. L.; Shih, M. C.; Kuo, Y. H. 2,2’-Diphenyl-1-picrylhydrazyl radical-scavenging active components from adlay (Coix lachrymal-jobi L. var. ma-yuen Stapf) hulls. J. Agric. Food Chem. 2002, 50, 5850-5855. Lakshmanan, J.; Elmendorf, J. S.; Ozcan, S. Analysis of insulin-stimulated glucose uptake in differentiated 3T3-L1 adipocytes. In Methods in Molecular Medicine: Diabetes mellitus methods and protocols. 1st edition; Ozcan, S., Ed.; Human Press: Totowa, NJ, 2003; 83, 97-103. Lee, C.; Yim, M. B.; Chock, P. B.; Yim, H. S.; Kang, S.O. Oxidation-reduction properties of methylglyoxal-modified protein in relation to free radical generation. J. Biol. Chem. 1998, 273, 25272-25278. Lee, M. Y.; Lin, H. Y.; Cheng, F.; Chiang, W.; Kuo, Y. H. Isolation and characterization of new lactam compounds that inhibit lung and colon cancer cells from adlay (Coix lachrymal-jobi L. var. ma-yuen Stapf) bran. Food Chem. Toxicol. 2008, 46, 1933-1939. Li, S.C. Pen-t’sao kang mu (Systematic Pharmacopoeia). China. 1596. Lin, R. Y.; Reis, E. D.; Dore, A. T.; Lu, M.; Ghodsi, N.; Fallon, J. T.; Fisher, E. A.; Vlassara, H. Lowering of dietary advanced glycation end products (AGE) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice. Atherosclerosis. 2002, 163, 303–311. Lin, Y.; Berg, A. H.; Iyengar, P.; Lam, T. K. T.; Giacca, A.; Combs, T. P.; Rajala, M. W.; Du, X.; Rollman, B.; Li, W.; Hawkins, M.; Barzilai, N.; Rhodes, C. J.; Fantus, G.; Brownlee, M.; Scherer, P. E. J. Biol. Chem. 2005, 280, 4617-4626. Lindsay, R. M.; Smith, W.; Lee, W. K.; Dominiczak, M. H.; Baird, J. D. The effect of δ-gluconolactone, an oxidized analogue of glucose, on the nonenzymatic glycation of human and rat haemoglobin. Clinica Chimica Acta. 1997, 263, 239-247. Liu, B. F.; Myata, S.; Hirota, Y.; Higo, S.; Miyazaki, H.; Fukunaga, M.; Hamada, Y.; Ueyama, S.; Muramoto, O.; Uriuhara, A.; Kasuga, M. Methylglyoxal induces apoptosis through activation of p38 mitogen-activated protein kinase in rat mesangial cells. Kidney Int. 2003, 63,947-957. Lo, C. Y.; Li, S.; Tan, D.; Pan, M. H.; Sang, S.; Ho, C. T. Trapping reactions of reactive carbonyl species with tea polyphenols in simulated physiological conditions. Mol. Nutr. Food Res. 2006, 50, 1118-1128. Lu, M.; Kuroki, M.; Amano, S.; Tolentino, M.; Keough, K.; Kim, I.; Bucala, R.; Adamis, A. P. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J. Clin. Invest. 1998, 101, 1219-1224. Manuel, Y.; Keenoy, B.; Vertommen, J.; De Leeuw, I. The effect of flavonoid treatment on the glycation and antioxidant status in Type 1 diabetic patients. Diabetes Nutr. Metab. 1999, 12, 256-263. Marota, K.; Terao, J. Antioxidative flavonoid quercetin: implication of its intestinal absorption and metabolism. Arch. Biochem. Biophys. 2003, 417, 12-17. Matsubara, L.; Ishihara, K.; Mizushina, Y.; Mori, M.; Nakajima, N. Anti-angiogenic activity of quercetin an its derivatives. Lett. Drug. Des. Discov. 2004, 1, 329-333. Matsuda, H.; Wang, T.; Managi, H.; Yoshikawa, M. Structural requirements of flavonoids for inhibition of protein glycation and radical scavenging activities. Bioorg. Med. Chem. 2003, 11, 5317-5323. Matsuura, N.; Aradate, A.; Sasaki, C.; Kojima, H.; Ohara, M.; Hasegawa, J.; Ubukata, M. Screening system for the Maillard reaction inhibitor from natural product extracts. J. Health Sci. 2002, 48, 520-526. Mukherjee, P. K.; Saha, K., Das, J., Pal, M., Saha, B. P. Studies on the anti-inflammatory activity of rhizomes of Nelumbo nucifera. Planta Medica. 1997b. 63, 367–369. Mukherjee, P. K., Saha, K., Saha, B. P. Effect of Nelumbo nucifera rhizome extract on blood sugar level in rats. J. Ethnopharmacol. 1997a, 58, 207–213. Murata, T.; Nagai, R.; Ishibashi, T.; Inomuta, H.; Ikeda, K.; Horiuchi, S. The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia. 1997, 40, 764-769. Nagaraj, R. H.; Shipanova, I. N.; Faust, F. M. Protein cross-linking by the Maillard reaction: isolation, characterization and in vivo detection of lysine-lysine cross-linked derived from methylglyoxal. J. Biol. Chem. 1996, 271, 19338-19345. Nagao T, Otsuka H, Kohda H, Sato T, Yamaski K. Benzoxazinones from Coix lachrymal-jobi L var. ma-yuen. Phytochem. 1985, 24, 2959-2962. Nass, N.; Bartling, B.; Navarrete Santo, A.; Scheubel, R. J.; Borgermann, J.; Silber, R. E.; Simm, A. Advanced glycation end products, diabetes and ageing. Z Gerontol Geriat. 2007, 40, 349-356. Nguyen, C. V. Toxicity of the AGEs generated from the Maillard reaction: on the relationship of food-AGEs and biological AGEs. Mol. Nutr. Food Res. 2006, 50, 1140-1149. Ohgami, N.; Nagai, R.; Ikemoto, M.; Arai, H., Kuniyasu, A., Horiuchi, S., Nakayama, H. CD36, a member of the class B scavenger receptor family, as a receptor for advanced glycation end products. J. Biol. Chem. 2001, 276, 3195-3202. Oldfield, M. D.; Bach, L. A.; Forbes, J. M.; Nikolic-Paterson, D.; McRobert, A.; Thalas, V.; Atkins, R. C.; Osicka, T.; Jerums, G.; Cooper, M. E. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J. Clin. Invest. 2001, 108, 1853-1863. Ono, Y.; Hattori, E.; Fukaya, Y.; Imai, S.; Ohizumi, Y. Anti-obesity effect of Nelumbo nucifera leaf extract in mice and rats. J. Ethnopharmacol. 2006, 106, 238-244. Peng, X; Zheng, Z.; Cheng, K.; Shan, F.; Ren, G.; Cheng, F.; Wang, M. Inhibitory effect of mung bean extract and its constituents vitexin and isovitexin on the formation of advanced glycation endproducts. Food Chem. 2008a, 106, 475-481. Peng, X; Cheng, K. W; Ma, J; Chen, B; Ho, C. T.; Lo, C; Chen, F; Wang, M. Cinnamon bark proanthocyanidins as reactive carbonyl scavengers to prevent the formation of advanced glycation endproducts. J. Agric. Food Chem. 2008b, 56, 1907-1911. Peppa, M.; Brem, H.; Cai, W.; Zhang, J. G.; Basgen, J.; Li, Z.; Vlassara, H.; Uribarri, J. Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711). Am. J. Nephrol. 2006, 26, 430-436. Plumb, G. W.; Price, K. R.; Williamson, G. Antioxidant properties of flavonol glycoside from green beans. Reox Rep. 1999, 4, 123-127. Ramasamy, R.; Vannucci, S. J.; Yan, S. S. D; Herold, K.; Yan, S. F.; Schmidt, A. M. Review: Advanced glycation end products and RAGE: a common thread in aging diabetes, neurodegeneration, and inflammation. Glycobio. 2005, 15, 16R-28R. Randell, E. W.; Vasdev, S.; Gill, V. Measurement of methylglyoxal in rat tissues by electrospray ionization mass spectrometry and liquid chromatography. J. Pharmacol. Toxicol. Methods. 2005, 51, 153-157. Reddy, V. P.; Beyaz, A. Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases. Drug Discov. Today. 2006, 11, 647-654. Riboulet-Chavey, A.; Pierron, A.; Durand, I.; Murdaca, J.; Giudicelli, J.; Obberghen, E. V. Methyglyoxal impairs the insulin signaling pathways independently of the formation of intracellular reactive oxygen species. Diabetes. 2006, 44, 1289-1299. Rice-Evans, C. A.; Miller, N. J.; and Paganga, G. Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic. Biol. Med. 1996, 20, 933-956. Rudich, A.; Kozlovsky, N.; Potashnik, R.; Bashan, N. Oxidant stress reduces insulin responsiveness in 3T3-L1 adipocytes. Am. J. Physiol. Endocrinol. Meta. 1997. 272, E935-E940. Russo, A.; Acquaviva, R.; Campisi, A.; Sorrenti, V.; Di Giacomo, C.; Virgata, G.; Barcellona, M. L.; Vanella, A. Bioflavonoids as antiradicals, antioxidants and DNA cleavage protectors. Cell Biol. Toxicol. 2000, 16, 91-98. Saija, A.; Tomaino, A.; Trombetta, D.; De Pasquale, A.; Uccella, N.; Barbuzzi, T.; Paolino, D.; Bonina, F. In vitro and in vivo evaluation of caffeic and ferulic acids as topical photoprotective agents. Int. J. Pharm. 2000, 199, 39–47. Saltiel, A. R.; Kahn, C. R. Insulin signaling and the regulation of glucose and lipid metabolism. Nature. 2001, 414, 799-806. Shibata, H.; Sakamoto, Y.; Oka, M.; Kono, Y. Natural antioxidant chlorogenic acid protects against DNA breakage caused by monochloramine. Biosci. Biotechnol. Biochem. 1999, 63, 1295-1297. Shinha, S.; Mukherjee, P. K.; Mukherjee, K.; Pal, M.; Mandal, S. C.; Saha, B. P. Evaluation of antipyretic potential of Nelumbo nucifera stalk extract. Phytother. Res. 2000, 14, 272–274. Shirai, M.; Yamanishi, R.; Moon, J. H.; Murota, K.; Terao, J. Effect of quercetin and its conjugate metabolite on the hydrogen peroxide-induced intracellular production of reactive oxygen species in mouse fibroblasts. Biosci. Biotechnol. Biochem. 2002, 66, 1015-1021. Sohn, D. H., Kim, Y. C., Oh, S. H., Park, E. J., Li, X., Lee, B. H. Hepatoprotective and free radical scavenging effects of Nelumbo nucifera. Phytomedicine. 2003, 10, 165–169. Soro-Paavonen, A.; Watson, A. M.; Li, J.; Paavonen, K.; Koitka, A.; Calkin, A. C.; Barit, D.; Coughlan, M. T.; Drew, B. G.; Lancaster, G. I.; Thomas, M.; Forbes, J. M.; Nawroth, P. P.; Bierhaus, A.; Cooper, M. E.; Jandeleit-Dahm, K. A. RAGE deficiency attenuates the development of atherosclerosis in diabetes. Diabetes. 2008, Epub ahead of print. Soulis-Liparota, T.; Cooper, M. E.; Dunlop, M.; Jerums, G. The relative roles of advanced glycation, oxidation an aldose reductase inhibition in the development of experimental diabetic nephropathy in the development of experimental diabetic nephropathy in the Sprgue-Dawley rat. Diabetologia. 1995, 38, 387-394. Stitt, A. W. Advanced glycation: an important pathological event in diabetic and age related ocular diseases. Br. J. Ophthalmol. 2001, 85, 746-753. Szwergold, B. S.; Howell, S. K.; Beisswenger, P. J. Enzymatic deglycation—a new paradigm or an epiphenomenon?. Excerpta Medica Int. Congr. Ser. Kumamoto: Elsevier. 2002. 1245, 143–52. Takahashi, M.; Konno, C.; Hikino, H. Isolation and hypoglycemic activity of coixan A, B, C, glycans of Coix lachryma-jobi var. ma-yuen seed. Planta Med. 1986, 52, 63-65. Takeuchi, M.; Bucala, R.; Suzuki, T.; Ohkubo, T.; Yamazaki, M.; Koike, T.; Kameda, Y.; Makita, Z. Neurotoxicity of advanced glycation end-products for cultured cortical neurons. J. Neuropathol. Exp. Neurol. 2000, 59, 1094-1105. Tsuchida, K.; Makita, Z.; Yamagishi, S.; Atsumi, T.; Miyoshi, H.; Obara, S.; Ishia, M.; Ishikawa, S.; Yasumura, K.; Koike, T. Suppression of transforming growth factor β and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advance glycation end product inhibitor, OPB-9195. Diabetologia. 1999, 42, 579-588. Thermo Fisher Scientific Inc. Instructions: Pierce® BCA Protein Assay Kit 23225/23227. Rockford, IL, 2007. Unno, Y.; Sakai, M.; Sakamoto, Y.; Kuniyasu, A.; Nakayama, H.; Nagai, R.; Horiuchi, S. Advanced glycation end products-modified proteins and oxidized LDL mediate down-regulation of leptin in mouse adipocytes via CD36. Biochem. Biophys. Res. Commun. 2004, 325, 151-156. Unoki, H.; Bujo, H.; Yamagishi, S.; Takeuchi, M.; Imaizumi, T.; Saito, Y. Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes. Diabetes Res. Clin. Pract. 2007, 76, 236-244. Urios, P.; Grigorova-Borsos, A. M.; Sternberg, M. Flavonoids inhibit the formation of the cross-linking AGE pentosidine in collagen incubated with glucose, according to their structure. Eur. J. Nutr. 2007, 46, 139-146. Vaya, J.; Mahmood, S.; Goldblum, A.; Aviram, M.; Volkova, N.; Shaalan, A.; Musa, R.; Tamir, S. Inhibition of LDL oxidation by flavonoids in relation to their structure and calculated enthalpy. Phytochem. 2003, 62, 89-99. Vinson, J. A.; Howard III, T. B. Inhibition of protein glycation and advanced glycation end products by ascorbic acid and other vitamins and nutrients. Nutr. Biochem. 1996, 7, 659-663. Vlassara, H.; Palace, M. R. Diabetes and advanced glycation endproducts. J Intern Med. 2002, 251, 87-101. Vlassara, H.; Striker L. J.; Teichberg, S.; Fuh, H.; Li, Y. M.; Steffes, M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc. Natl. Acad. Sci.US. 1994, 91, 11704-11708. Wirasathien, L; Pengsuparp, T; Suttisri, R; Ueda, H; Moriyasu, M.; Kawanishi, K. Inhibitors of aldose reductase and advanced glycation end-products formation from the leaf of Stelechocarpus cauliflorus R.E. Fr. Phytomedicine. 2007, 14, 546-550. World Health Organization. Fact sheet No. 312 “Diabetes”. 2006. Switzerland. Wu, C. H.; Yen, G. C. Inhibitory effect of naturally occurring flavonoids on the formation of advanced glycation endproducts. J. Agric. Food Chem. 2005, 53, 3167-3173. Wu, M. J.; Wang, L.; Weng, C. Y.; Yen, J. H. Antioxidant activity of methanol extract of the lotus leaf (Nelumbo nucifera Gertn.). Am. J. of Chin. Med. 2003, 31, 687–698. Wu, Y. J. Effect of lotus leaf methanolic extract on pancreatic lipase activity and differentiation of 3T3-L1 preadipocytes. Master thesis of the National Taiwan University Graduate Institute of Food Science and Technology: Taipei, Taiwan, 2007. Xi, M.; Hai, C.; Tang, H.; Chen, M.; Fang, K.; Liang, X. Antioxidant and antiglycation properties of total saponins extracted from traditional Chinese medicine used to treat Diabetes mellitus. Phtother. Res. 2008, 22, 228-237. Yan, S. F.; Ramasamy, R.; Schmidt, A. M. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab. 2008, 4, 285-293. Yokozawa, T.; Nakagawa, T. Inhibitory effects of Luobuma tea and its components against glucose-mediated protein damage. Food Chem. Toxicol. 2004, 42, 975-981. Zheng, F.; He, C.; Cai, W.; Hattori, M.; Steffes, M.; Vlassara, H. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab Res Rev. 2002, 18, 224-237 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/40718 | - |
dc.description.abstract | 糖尿病為一新陳代謝異常相關之疾病,主要為胰島素利用率不佳或胰島素分泌不足,所造成的慢性高血糖。糖化終產物(advanced glycation end products, AGEs)生成的機制與糖尿病併發症有關。糖化終產物會與細胞上的受體結合,增加氧化壓力並活化釋放前發炎物質與細胞激素之訊息傳導路徑、形成不可逆的AGE蛋白質並改變蛋白質與酵素之結構使其失去活性。荷葉與薏仁因其豐富的生理活性,可望作為糖尿病病患平日之保健食品。因此,本實驗之目的在篩選荷葉及薏苡籽實中之有效抗糖基化成分並檢視AGEs是否會對脂肪細胞之葡萄糖代謝能力造成不良影響。以BSA-Glucose assay模擬體內最終形成的AGE之篩選結果顯示,薏苡種皮乙醇萃取物之正丁醇區分物的次區分物C與D (ATE-Bu-C, ATE-Bu-D)有最高的抗蛋白糖基化活性。在荷葉甲醇萃取物(LLM)方面,以正丁醇區分物的次區分物4、 5與6 (LLMB 4, LLMB 5, LLMB 6)之抗蛋白糖基化效果最為顯著。從所有選定之次區分物內已分出來的純化合物裡,以槲皮素、兒茶素、咖啡酸及綠原酸有最高的抗蛋白糖基化活性。因此,ATE-Bu-C、ATE-Bu-D、LLMB 4、LLMB 5、LLMB 6、槲皮素、兒茶素、咖啡酸及綠原酸被選定進入下階段的實驗。以Hemoglobin-δ-gluconolactone assay模擬體內早期AGE形成試驗結果顯示,綠原酸及兒茶素具有25%及23%抑制早期蛋白糖基化反應之功效,且它們的功效與正控制aminoguanidine的效果是相當的(23%)。繼續評估選定之有效次區分物及純化合物是否具有抑制MGO (Methylglyoxal)反應或與MGO直接螯合之能力來模擬抑制體內中期AGE形成的效果。結果指出,咖啡酸擁有最佳之抑制MGO糖化蛋白質之能力,但兒茶素(2.5 mM)有最佳之與MGO直接結合的能力(85%)。然而,咖啡酸與綠原酸皆不具有與MGO直接形成adduct的能力。ATE-Bu-C及ATE-Bu-D並沒有任何與MGO形成adduct的能力,但LLMB 4、LLMB 5及LLMB 6約有21至28%的抑制率。經HPLC定量結果顯示,LLMB 4與LLMB 5各含0.032 mM與0.039 mM之兒茶素。據此推測,LLMB 4與LLMB 5螯合MGO之能力最少有部分與其兒茶素含量有關。MGO之生成會對細胞造成毒性,因此本實驗評估MGO對3T3-L1脂肪細胞之細胞株之毒性。結果顯示,MGO在濃度2 mM以下無細胞毒性,因此以1 mM及2 mM的MGO探討其對3T3-L1葡萄糖攝取之能力影響。經過36小時的1 mM及2 mM MGO處理,3T3-L1葡萄糖攝取之能力降至控制組的52%及40%。 從這個結果推測,AGEs的確與胰島素抗性具有相關性。綜上所述,薏仁可抑制早期與中期之AGE形成,其主要作用次區分物為ATE-Bu- C與ATE-Bu-D,其主要作用成分應來自於綠原酸及咖啡酸;荷葉亦可抑制早期與中期之AGE形成並與MGO形成聚合物,其主要作用次區分物為 LLMB 4、LLMB 5與LLMB 6,其主要作用成分應來自
於槲皮素及兒茶素。 | zh_TW |
dc.description.abstract | Diabetes mellitus is a metabolism disorder characterized by chronic hyperglycemia due to inefficient action of insulin or insufficient production of insulin. One of the mechanisms proposed for diabetic complication is the formation of advanced glycation end products, known as AGE. AGE could bind with cellular receptors, increase oxidative stress and activate pathways that release proinflammatory compounds and cytokines, form irreversible AGE-proteins and finally modify proteins and enzymes and deactivate their functions. Lotus leaf and adlay have numerous biological activities and are potential supplements for diabetic patients. Therefore, the objective of this study was to screen antiglycative agents from lotus leaf and adlay seed using in vitro experiments and examine the effects of AGE on glucose uptake of adipocytes. Based on in vitro BSA-Glucose assay, which simulates the in vivo AGE formation, ethanolic extract of adlay testa demonstrated a high inhibitory effect against AGE formation, especially in butanol subfractions C and D (ATE-Bu-C, ATE-Bu-D). Butanol subfractions 4, 5 and 6 from methanolic extract of lotus leaf had the highest inhibitory effects against AGE formation (LLMB 4, LLMB 5, LLMB 6). Amongst all the compounds isolated from these subfractions up to date, quercetin, catechin, caffeic acid and chlorogenic acid demonstrated high capabilities to inhibit AGE formation. Therefore, ATE-Bu-C, ATE-Bu-D, LLMB 4, LLMB 5, LLMB 6, catechin, quercetin, chlorogenic acid and caffeic acid were selected for the next stage of this study. From hemoglobin-δ-gluconolactone assay, which simulates the in vivo early stage of AGE formation, chlorogenic acid and catechin were the better early glycation inhibitors with inhibitory percentage of 25% and 23%, which were comparable to the inhibitory effect of the positive control aminoguanidine (23%). Effective subfractions and compounds were then examined on their abilities to inhibit MGO via MGO-BSA assay and MGO trapping capacity, which simulate the middle stage of AGE formation. Catechin (2.5 mM) demonstrated a 85% MGO (1.5 mM) trapping ability. Although caffeic acid had the highest inhibition against MGO-mediated protein modification, catechin demonstrated the strongest MGO trapping abilities with an inhibitory percentage of 85% at 2.5 mM. Chlorogenic acid and caffeic acid did not exhibit any MGO trapping abilities. ATE-Bu-C and ATE-Bu-D did not demonstrate much MGO trapping capability whereas LLMB 4, LLMB 5 and LLMB 6 demonstrated 21 to 28% MGO inhibition abilities. Based on HPLC analysis, catechin concentrations were determined to be 0.032 mM and 0.039 mM in LLMB 4 and LLMB 5. Hence, MGO trapping abilities of LLMB 4 and LLMB 5 were at least partially came from catechin. MGO had been demonstrated to be cytotoxic to cells and its cytotoxicity was examined in 3T3-L1 as well. Concentrations of MGO below 2 mM did not appear to have any detectable cytotoxic effects on the viability of 3T3-L1. Therefore, 1 mM and 2 mM of MGO were used to evaluate MGO’s effects on the glucose uptake of 3T3-L1. The glucose uptake ability of 3T3-L1 progressively decreased to 52% and 40% of the control group respectively after 36 hours of 1 mM and 2 mM MGO treatment. This result suggested that AGEs are involved in the development of impaired insulin sensitivity in adipocytes. In conclusion, adlay inhibits the early and middle stage of glycation. The primary effective subfractions were ATE-Bu-C and ATE-Bu-D and the major effective pure compounds were chlorogenic acid and caffeic acid. Lotus leaf also inhibits the early and middle stage of glycation and it traps MGO as well. The primary effective subfractions were LLMB 4, LLMB 5 and LLMB 6 and the major effective compounds were quercetin and catechin. | en |
dc.description.provenance | Made available in DSpace on 2021-06-14T16:57:17Z (GMT). No. of bitstreams: 1 ntu-97-R95641039-1.pdf: 11218789 bytes, checksum: aab316490d02f9178b19b86be5e37bb2 (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | 謝辭 i
中文摘要 ii Abstract iv Table of Contents vi Index of Figures x Index of tables xii Abbreviation xiii Chapter 1 Background and Paper Review 1 1.1 Advanced Glycation End Products 1 1.1.1 Endogenous formation of advanced glycation end products 1 1.1.2 Exogenous sources of AGEs 3 1.1.3 Effects of AGEs on human body 3 1.1.4 In vivo defense system against AGEs 8 1.1.5 Possible mechanisms behind AGE inhibition 8 1.2 Diabetes Mellitus 10 1.2.1 About diabetes mellitus 10 1.2.2 Diagnostic criteria and current treatments for diabetes 11 1.2.3 Insulin regulates glucose metabolism 12 1.3 The Role of AGEs in Progression and Complications of Diabetes Mellitus and Other Diseases 17 1.3.1 AGEs and diabetic complications 17 1.3.1.1 AGEs and nephropathy 17 1.3.1.2 AGEs and retinopathy 18 1.3.1.3 AGEs and neuropathy 18 1.3.1.4 AGEs and cardiovascular diseases 19 1.3.2 AGEs, Adipocytes and Insulin resistance 19 1.3.3 AGEs and other Diseases 21 1.3.4 Targeting the AGE pathway as potential intervention for diabetic complications 21 1.4 Lotus leaf and adlay 24 1.4.1 Lotus leaf – General information 24 1.4.2 Lotus leaf– Composition 24 1.4.3 Lotus leaf– Biological and pharmacological activities 24 1.4.4 Adlay – General information 25 1.4.5 Adlay – Composition 26 1.4.6 Adlay - Biological and pharmacological activities 26 Chapter 2 Objective of Research 28 2.1 Experimental objectives 28 2.2 Experimental design 28 Chapter 3 Materials and Methods 30 3.1 Adlay 30 3.1.1 Source of Adlay 30 3.1.2 Preparation of adlay extracts 30 3.2 Lotus leaf 33 3.2.1 Source of lotus leaf 33 3.2.2 Preparation of lotus leaf extracts 33 3.3 BSA-glucose Assay 34 3.3.1 Principle of analysis 34 3.3.2 Chemicals and equipments 34 3.3.2.1 Chemicals 35 3.3.2.2 Equipments 35 3.3.3 Quercetin as the positive control 35 3.3.4 Protocol 36 3.4 Hemoglobin-δ-gluconolactone assay 36 3.4.1 Principle of analysis 36 3.4.2 Chemicals and equipments 37 3.4.2.1 Chemicals 37 3.4.2.2 Equipments 37 3.4.3 Protocol 37 3.5 BSA-MGO assay 38 3.5.1 Principle of analysis 38 3.5.2 Chemicals and equipments 38 3.5.2.1 Chemicals 38 3.5.2.2 Equipments 39 3.5.3 Protocol 39 3.6 Evaluation of direct MGO trapping capacity 40 3.6.1 Principle of analysis 40 3.6.2 Chemicals and equipments 40 3.6.2.1 Chemicals 41 3.6.2.2 Equipments 41 3.6.3 Protocol 41 3.7 Quantification of flavonoids in the selected subfractions via HPLC analysis 42 3.7.1 Quantification of flavonoids 42 3.7.2 Chemicals and equipments 43 3.7.2.1 Chemicals 43 3.7.2.2 Equipments 43 3.7.3 Protocol 43 3.8 Cell line 3T3-L1 44 3.8.1 Source of Cell line 44 3.8.2 Background about cell line 3T3-L1 44 3.8.3 Chemicals and equipments 45 3.8.3.1 Chemicals 45 3.8.3.2 Equipments 45 3.8.4 Protocol 46 3.8.4.1 Maintenance of 3T3-L1 46 3.8.4.2 Cryogenic preservation of 3T3-L1 47 3.8.4.3 Defrost of 3T3-L1 47 3.8.4.4 Differentiation of 3T3-L1 48 3.9 MTT ASSAY 49 3.9.1 Principle of analysis 49 3.9.2 Chemicals and equipments 49 3.9.2.1 Chemicals 49 3.9.2.2 Equipments 49 3.9.3 Protocol 50 3.10 Isotope-labeled glucose uptake assay 50 3.10.1 Principle of analysis 50 3.10.2 Chemicals and equipments 51 3.10.2.1 Chemicals 51 3.10.2.1 Equipments 51 3.10.3 Protocol 52 3.11 Determination of protein concentration by BCA assay 53 3.11.1 Principle of analysis 53 3.11.2 Chemicals and equipments 53 3.11.2.1 Chemicals 53 3.11.2.2 Equipments 54 3.11.3 Protocol 54 3.12 Statistics 54 Chapter 4 Results and Discussion 55 4.1 BSA-Glucose Assay 55 4.1.1 Screening of adlay based on BSA-glucose assay 55 4.1.2. Screening of lotus leaf based on BSA-glucose assay 66 4.1.3 The selected effective inhibitors based on results obtained from BSA-glucose assay 72 4.2 Hemoglobin-δ-gluconolactone assay 76 4.3 BSA-MGO assay 78 4.4 Evaluation of MGO trapping abilities 82 4.5 Quantification of catechin in LLMB subfractions via HPLC analysis 91 4.6 3T3-L1: Treatment on cell viability based on MTT assay 94 4.7 Glucose uptake assay 98 Conclusion 101 Future Perspective 103 Reference 104 Appendix 119 | |
dc.language.iso | en | |
dc.title | 薏苡籽實與荷葉之抗糖基化效應 | zh_TW |
dc.title | Effects of fractions from adlay seed and lotus leaf extracts on antiglycation | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 何其儻,孫璐西,龔瑞林,鄭心嫻 | |
dc.subject.keyword | 薏苡籽實,荷葉,3T3-L1脂肪細胞,糖尿病,糖化終產物,葡萄糖攝取, | zh_TW |
dc.subject.keyword | adlay seed,lotus leaf,3T3-L1 adipocytes,diabetes mellitus,advanced glycation end products,glucose uptake, | en |
dc.relation.page | 140 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2008-07-30 | |
dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
dc.contributor.author-dept | 食品科技研究所 | zh_TW |
顯示於系所單位: | 食品科技研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-97-1.pdf 目前未授權公開取用 | 10.96 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。